In-Depth Examination Of 18 Analyst Recommendations For Amgen
Portfolio Pulse from Benzinga Insights
Amgen (NASDAQ:AMGN) received 18 analyst ratings in the last quarter, with an average 12-month price target of $293.06, a high of $326.00, and a low of $240.00. The ratings included 4 bullish, 6 somewhat bullish, and 8 indifferent, with no bearish ratings. Notably, the average price target increased by 5.07% over the past month. Analysts' actions included raising, maintaining, and lowering their stances, reflecting their views on Amgen's market position. Amgen's financial performance shows a revenue growth rate of 3.77%, a net margin of 25.06%, an ROE of 23.97%, and an ROA of 1.91%, but a high debt-to-equity ratio of 7.9.
December 19, 2023 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amgen's stock may see a positive short-term impact due to the overall bullish sentiment from analysts and the recent increase in the average price target. The company's solid financial performance, with good revenue growth and high net margin, supports this outlook, although the high debt-to-equity ratio could be a concern for some investors.
The positive analyst ratings and raised price targets suggest a bullish sentiment, which typically leads to a positive short-term impact on the stock price. The financial metrics indicate strong performance, which can reassure investors. However, the high debt-to-equity ratio may temper some of the optimism, but it doesn't seem to outweigh the positive factors in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100